David Bautz

Joe Pantginis

Keith Markey

Michael Higgins

- Armata Pharmaceuticals, Inc. (ARMP) announced **positive results** from its recently completed **Phase 2a diSArm study of AP-SA02** for complicated *Staphylococcus aureus* bacteremia, presented at IDWeek 2025TM on **October 22, 2025**.  **[921114_0001104659-25-101447_tm2529060d1_ex99-1.htm:1]** 
- The study demonstrated **higher Day 12 clinical response rates** for the AP-SA02 group (**88%**) compared to the placebo group (**58%**).  **[921114_0001104659-25-101447_tm2529060d1_ex99-1.htm:1]** 
- Patients treated with AP-SA02 showed **no non-response or relapse** (0%) at one week post-BAT or at End of Study, in contrast to approximately **25% in the placebo group**.  **[921114_0001104659-25-101447_tm2529060d1_ex99-1.htm:2]** 
- AP-SA02 was **well-tolerated** with no serious adverse events related to the study drug, and these findings **strongly support advancing to a pivotal Phase 3 trial** planned for **2026**.  **[921114_0001104659-25-101447_tm2529060d1_ex99-1.htm:2]**

Armata Pharmaceuticals Highlights Positive Phase 2a diSArm Study Results for AP-SA02

- Armata Pharmaceuticals highlighted **positive results** from its recently completed Phase 2a diSArm study of **AP-SA02** as a potential treatment for complicated *Staphylococcus aureus* bacteremia (SAB) at IDWeek 2025.  **[921114_20251022LA03517:0]** 
- The study demonstrated **higher day 12 clinical response rates** in the AP-SA02 group, with **88%** (21/24) assessed by blinded site investigators and **83%** (20/24) by the blinded Adjudication Committee, compared to **58%** (7/12) in the placebo group for both assessments.  **[921114_20251022LA03517:0]** 
- **No patients** in the AP-SA02 group experienced non-response or relapse (0%) at one week post-BAT or End of Study, contrasting with approximately **25%** in the placebo group.  **[921114_20251022LA03517:1]** 
- AP-SA02 was **well-tolerated**, with no serious adverse events related to the study drug.  **[921114_20251022LA03517:1]** 
- The company plans to initiate a pivotal **Phase 3 trial in 2026**, subject to review and feedback from the U.S. Food and Drug Administration (FDA), based on these results.  **[921114_20251022LA03517:1]**

- Armata Pharmaceuticals' AP-SA02 demonstrated **significantly improved clinical outcomes** in its Phase 1b/2a "diSArm" study for complicated *Staphylococcus aureus* bacteremia, showing an **88% responder rate** (a **30 percentage point increase** over best available therapy alone) and **100% clinical response** at later timepoints, with **no serious adverse events related to the drug**.     
- The company completed its NCFB Phase 2 Tail wind Study for AP-PA02 in **Q3 2024**, which showed a **significant reduction in *P. aeruginosa* density** in treated subjects.    
- As of **June 30, 2025**, Armata Pharmaceuticals reported **$4.3 million** in unrestricted cash and cash equivalents, which does not include an additional **$15 million** received on **August 11, 2025**.

Armata Pharmaceuticals announces positive Phase 1b/2a clinical trial results for AP-SA02 and provides financial update

- **Insmed's BRINSUPRI (brensocatib) received FDA approval in August 2025**, becoming the **first-ever therapy** for non-cystic fibrosis bronchiectasis (NCFB) and the first drug targeting DPP1, addressing a market with high unmet medical needs.  **[921114_114f8a8a415b41418c18d8c77b7b319d_0]** **[921114_114f8a8a415b41418c18d8c77b7b319d_1]** 
- This approval is expected to significantly impact the NCFB market, which was valued at **USD 1.5 billion in 2024** across key geographies and is projected to grow at an **11.7% CAGR** in the US during 2020–2034.  **[921114_114f8a8a415b41418c18d8c77b7b319d_0]**  BRINSUPRI itself is anticipated to achieve peak sales of **~USD 5 billion**.  **[921114_114f8a8a415b41418c18d8c77b7b319d_2]** 
- The approval has intensified competition in the NCFB market, with other companies, including **Armata Pharmaceuticals**, also actively working on innovative NCFB drugs and advancing therapies like DPP1 inhibitors.  **[921114_114f8a8a415b41418c18d8c77b7b319d_0]** **[921114_114f8a8a415b41418c18d8c77b7b319d_2]** **[921114_114f8a8a415b41418c18d8c77b7b319d_3]**

Armata Pharmaceuticals (ARMP)